<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04558502</url>
  </required_header>
  <id_info>
    <org_study_id>2020-584</org_study_id>
    <nct_id>NCT04558502</nct_id>
  </id_info>
  <brief_title>Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter Pylori Eradication</brief_title>
  <official_title>Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy as First-Line Regimen for Helicobacter Pylori Eradication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although,bismuth-containing quadruple therapy has been highly recommended as first-line&#xD;
      treatment regimen for H.pylori infection,it also has its problems and limitations in&#xD;
      China.The primary resistance rates of metronidazole,clarithromycin and levofloxacin are all&#xD;
      high in China.Besides that,tetracycline cannot be obtained and its complicated administration&#xD;
      (four times daily) easily reduce patient compliance. In this study, we proposed to evaluate&#xD;
      the eradication rate, safety, and compliance of a minocycline-based bismuth quadruple&#xD;
      regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 226 H. pylori-infected, treatment-naive patients will be enrolled in this&#xD;
      randomized controlled clinical trial. Patients will be randomly allocated into 2 groups:&#xD;
      Esomeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1000 mg, and bismuth potassium citrate&#xD;
      200 mg twice daily for 14 days.Esomeprazole 20 mg, minocycline 100 mg, amoxicillin 1000 mg,&#xD;
      and bismuth potassium citrate 200 mg twice daily for 14 days. Eradication rates will be&#xD;
      assessed 4-12 weeks after treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 5, 2020</start_date>
  <completion_date type="Anticipated">July 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 5, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate</measure>
    <time_frame>4-12 weeks after treatment</time_frame>
    <description>Helicobacter pylori eradication of minocycline-containing bismuth quadruple therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse effects</measure>
    <time_frame>3-7 days after treatment</time_frame>
    <description>incidence of adverse effects of minocycline-containing bismuth quadruple therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">226</enrollment>
  <condition>Helicobacter Pylori Eradication</condition>
  <arm_group>
    <arm_group_label>minocycline-based bismuth quadruple regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esomeprazole 20 mg, minocycline 100 mg, amoxicillin 1000 mg, and bismuth potassium citrate 200 mg twice daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clarithromycin-based bismuth quadruple regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esomeprazole 20 mg,clarithromycin 500 mg, amoxicillin 1000 mg, and bismuth potassium citrate 200 mg twice daily for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline hydrochloride capsule</intervention_name>
    <description>14-day minocycline-based bismuth quadruple regimen</description>
    <arm_group_label>minocycline-based bismuth quadruple regimen</arm_group_label>
    <other_name>Meiman</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>14-day clarithromycin-based bismuth quadruple regimen</description>
    <arm_group_label>clarithromycin-based bismuth quadruple regimen</arm_group_label>
    <other_name>Klacid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  H.pylori-positive outpatients with endoscopically proven chronic gastritis&#xD;
&#xD;
          -  H. pylori (+) determined by either the 14C-or 13C-urea breath test or the gastric&#xD;
             mucosal tissue rapid urease test and pathological section staining&#xD;
&#xD;
          -  Treatment-naive patients for eradication of H.pylori infection&#xD;
&#xD;
          -  Fully informed and agreed to participate in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years or &gt;70 years&#xD;
&#xD;
          -  Allergy to any of the study drugs&#xD;
&#xD;
          -  Use of any drug that could influence the study results 4 weeks before the study,such&#xD;
             as antibiotics,bismuth agent,PPI or H2 receptor antagonist (H2RA)&#xD;
&#xD;
          -  Previous gastric or esophageal surgery&#xD;
&#xD;
          -  Patients with malignancy or severe comorbidity&#xD;
&#xD;
          -  Pregnancy,lactation or alcohol abuse&#xD;
&#xD;
          -  Patients with poor treatment compliance or could not express themselves correctly&#xD;
&#xD;
          -  Participation in other clinical studies recently (within 3 months of enrollment in&#xD;
             this clinical study)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qin Du, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>2nd Affiliated Hospital,School of Medicine,Zhejiang University,China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Li, master</last_name>
    <phone>15906698496</phone>
    <email>liyan_8786@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuehua Han, PhD</last_name>
    <phone>13858126927</phone>
    <email>13858126927@163.com</email>
  </overall_contact_backup>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>September 20, 2020</last_update_submitted>
  <last_update_submitted_qc>September 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Eradication</keyword>
  <keyword>minocycline</keyword>
  <keyword>bismuth quadruple regimens</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

